Key facts
- Meco Diagnostics’s last known valuation is $12.0M (Dec 2025).
- It has raised $1.1M; the latest was Seed Round ($1.1M) in Dec 2025.
- Notable investors include Team Ignite Ventures, CONNECT (San Diego), GoAhead Ventures, EvoNexus, Startup San Diego — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Meco Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Meco Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Meco Diagnostics
Developer of predictive biomarker technology designed to enable antifibrotic therapy for early-stage breast cancer treatment. The company offers a clinically validated companion diagnostic platform, including the MeCo Score for treatment response prediction, enabling early-stage breast cancer patients and healthcare providers to pursue targeted antifibrotic therapy that supports long-term remission while reducing financial burden for patients and payers.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2022
- Employees
- 6
- Website
- mecodiagnostics.com/
- Ownership
- Privately Held (backing)
Meco Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Meco Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Meco Diagnostics in its N-PORT filings yet. We sweep new filings monthly.